GENE GUIDE

EP300-Related Syndrome

This guide is not meant to take the place of medical advice. Please consult with your doctor about your genetic results and health care choices. This Gene Guide was last updated on 2024. As new information comes to light with new research we will update this page. You may find it helpful to share this guide with friends and family members or doctors and teachers of the person who has EP300-Related Syndrome.
a doctor sees a patient

EP300-related syndrome is also called Rubinstein-Taybi syndrome 2 and Menke-Hennekam syndrome-2. For this webpage, we will be using the name EP300-related syndrome to encompass the wide range of variants observed in the people identified.

EP300-related syndrome happens when there are changes in the EP300 gene. These changes can keep the gene from working as it should.

A related gene called CREBBP has a similar function to the EP300 gene.

Key Role

The EP300 and CREBBP genes play a key role in controlling the activity of other genes.

Symptoms

Because the EP300 gene is important in brain development and function, many people who have EP300-related syndrome have:

  • Developmental delay
  • Intellectual disability
  • Speech delay
  • Smaller than average head size
  • Feeding issues
  • Lower than average muscle tone
  • Autism
  • Hyperactivity

EP300-related syndrome is a genetic condition, which means that it is caused by variants in genes. Our genes contain the instructions, or code, that tell our cells how to grow, develop, and work. Every child gets two copies of the EP300 gene: one copy from their mother’s egg, and one copy from their father’s sperm. In most cases, parents pass on exact copies of the gene to their child. But the process of creating the egg or sperm is not perfect. A change in the genetic code can lead to physical issues, developmental issues, or both.

Sometimes a spontaneous variant happens in the sperm, egg or after fertilization. When a brand new genetic variant happens in the genetic code is called a ‘de novo’ genetic variant. The child is usually the first in the family to have the genetic variant.

De novo variants can take place in any gene. We all have some de novo variants, most of which don’t affect our health. But because EP300 plays a key role in development, de novo variants in this gene can have a meaningful effect.

Research shows that EP300-related syndrome is often the result of a de novo variant in EP300. Many parents who have had their genes tested do not have the EP300 genetic variant found in their child who has the syndrome. In some cases, EP300-related syndrome happens because the genetic variant was passed down from a parent.

Autosomal dominant conditions

EP300-related syndrome is an autosomal dominant genetic condition. This means that when a person has the one damaging variant in EP300 they will likely have symptoms of EP300-related syndrome. For someone with an autosomal dominant genetic syndrome, every time they have a child there is a 50 percent chance they pass on the same genetic variant and a 50 percent chance they do not pass on the same genetic variant.

Autosomal Dominant Genetic Syndrome

GENE / gene
GENE / gene
Genetic variant that happens in sperm or egg, or after fertilization
GENE / gene
Child with de novo genetic variant
gene / gene
Non-carrier child
gene / gene
Non-carrier child

Why does my child have a change in the EP300 gene?

No parent causes their child’s EP300-related syndrome. We know this because no parent has any control over the gene changes that they do or do not pass on to their children. Please keep in mind that nothing a parent does before or during the pregnancy causes this to happen. The gene change takes place on its own and cannot be predicted or stopped.

Each family is different. A geneticist or genetic counselor can give you advice on the chance that this will happen again in your family.

The risk of having another child who has EP300-related syndrome depends on the genes of both biological parents.

  • If neither biological parent has the same genetic variant found in their child, the chance of having another child who has the syndrome is on average 1 percent. This 1 percent chance is higher than the chance of the general population. The increase in risk is due to the very unlikely chance that more of the mother’s egg cells or the father’s sperm cells carry the same genetic variant.
  • If one biological parent has the same genetic variant found in their child, the chance of having another child who has the syndrome is 50 percent.

For a symptom-free brother or sister of someone who has EP300-related syndrome, the sibling’s risk of having a child who has EP300-related syndrome depends on the sibling’s genes and their parents’ genes.

  • If neither parent has the same genetic variant causing EP300-related syndrome, the symptom-free sibling has a nearly 0 percent chance of having a child who would inherit EP300-related syndrome.

As of 2024, at least 214 people with EP300-related syndrome have been identified in a medical clinic. Scientists estimate that the condition happens in 1 in 100,000 to 1 in 125,000 live births.

Do people who have EP300 syndrome look different?

People who have EP300-related syndrome may look different. Appearance can vary and can include some but not all of these features:

  • Short height
  • A small head, also called microcephaly
  • Facial features that are different from those of other family members
  • Thick eyebrows
  • Wide thumbs that may be positioned differently on the hand
  • Big first toes

How is EP300 syndrome treated?

At this point, there are no medicines designed to treat the syndrome. A genetic diagnosis can help people decide on the best way to track the condition and manage therapies. Doctors can refer people to specialists for:

  • Genetics consults
  • Development and behavior studies
  • Neurological studies
  • Orthopedic studies

A developmental pediatrician, neurologist, or psychologist can follow progress over time and can help:

  • Suggest the right therapies. This can include physical, occupational, speech, or behavioral therapy.
  • Guide individualized education plans (IEPs).

Specialists advise that therapies for EP300-related syndrome should begin as early as possible, ideally before a child begins school.

People who have EP300-related syndrome may have a higher risk of developing tumors. These may be cancerous or non-cancerous. Your doctor can recommend whether you need additional screening or to consult a specialist.

In 2024, international experts collaborated on guidelines and care for people with Rubinstein-Taybi syndrome. Go to this link to read the recent recommendations, which include clinical criteria to distinguish between Rubinstein-Taybi syndrome and Menke-Hennekam syndrome. Feel free to share this with your medical team.

This section includes a summary of information from major published articles. It highlights how many people have different symptoms. To learn more about the articles, see the Sources and references section of this guide.

Behavior and development concerns linked to Rubinstein-Taybi syndrome caused by a variant in EP300

The information below includes information on Rubinstein-Taybi syndrome (RTS) caused by a variant in EP300. Variants in EP300 that cause Menke-Hennekam syndrome are summarized in the next section below. Variants that cause Menke-Hennekam syndrome are pathogenic missense variants or in-frame deletion variants in exons 30 and 31. Talk to your genetics team to find out what type of variant was identified in your family.

Speech and Learning

Almost all people with RTS EP300-related syndrome had developmental delay or intellectual disability (ID). People had mostly mild ID. People spoke their first words at an average age of 2 years.

  • 49 out of 52 people had developmental delay or intellectual disability (94 percent)

Behavior

Some people with RTS EP300-related syndrome had behavioral issues, such as autism, self-injurious behavior, and aggressive behavior. People were often described as motivated to interact with others and ‘overly-friendly’.

  • 13 out of 52 people had autism (25 percent)

Brain

Some people with RTS EP300-related syndrome had seizures, and more than one-half of people had non-specific abnormalities on electroencephalogram (EEG). Most had a smaller than average head size, also known as microcephaly. Some people with EP300-related syndrome had brain changes seen on magnetic resonance imaging (MRI).

  • 5 out of 52 people had seizures (10 percent)
  • 45 out of 52 people had microcephaly (87 percent)
10%
5 out of 52 people had seizures.
87%
45 out of 52 people had microcephaly.

Medical and physical concerns linked to Rubinstein-Taybi syndrome caused by a variant in EP300

Growth

Some people with RTS EP300-related syndrome were born with heart defects. This includes patent ductus arteriosus, persistent foramen ovale, and atrial and ventricular septal defect.

Often babies had delayed growth after birth, which appeared as a child dropping off the standard growth curve chart. In general, people did not have a growth spurt during puberty. Obesity was a problem for about one in three people.

  • 14 out of 52 people had heart defects (27 percent)
  • 34 out of 52 people had postnatal growth delay (66 percent)
  • 20 out of 52 people had obesity (39 percent)
27%
14 out of 52 people had heart defects.
66%
34 out of 52 people had postnatal growth delay.
39%
20 out of 52 people had obesity.

Gastrointestinal tract and urinary tract issues

It was common for people with RTS EP300-related syndrome to have constipation into adulthood. Some people had urinary tract issues, such as horseshoe kidney, renal duplication, kidney agenesis, kidney dysplasia, hydronephrosis, nephrolithiasis, and vesicoureteral reflux.

  • 28 out of 54 people had constipation (52 percent)
  • 13 out of 54 people had urinary tract defects (24 percent)

Behavior and development concerns linked to Menke-Hennekam syndrome

The information below includes information on Menke-Hennekam (MKHK) syndrome caused by a variant in EP300 or CREBBP. Variants in these two genes that cause Menke-Hennekam syndrome are pathogenic missense variants or in-frame deletion variants in exons 30 and 31. Talk to your genetics team to find out what type of variant was identified in your family.

Some researchers organize MKHK into sub-types. The information in this summary does not include sub-types.

Speech and Learning

Almost all people with MKHK syndrome had developmental delay or intellectual disability (ID). People spoke their first words at an average age of 2.6 years.

  • 39 out of 40 people had developmental delay or intellectual disability (98 percent)

Behavior

Many people with MKHK syndrome had behavioral issues, such as autism.

  • 27 out of 38 people had behavioral issues (71 percent)

Brain

Some people with MKHK syndrome had seizures.

  • 7 out of 43 people had seizures (16 percent)
Human head showing brain outline

Medical and physical concerns linked to Menke-Hennekam syndrome

Growth

Some people with MKHK syndrome were born with heart defects. People were often shorter than average, underweight, and had a smaller than average head circumference. Some babies were born premature and were smaller than average at birth.

  • 11 out of 42 people had heart defects (26 percent)
  • 6 out of 44 babies were born premature (14 percent)

Feeding and digestion

Many people with MKHK syndrome had feeding issues, constipation, and acid reflux.

  • 36 out of 43 people had feeding issues (84 percent)
  • 20 out of 37 people had constipation (54 percent)
  • 16 out of 35 people had acid reflux (46 percent)
84%
36 out of 43 people had feeding issues.
54%
20 out of 37 people had constipation.
46%
16 out of 35 people had acid reflux.

Musculoskeletal issues

People with MKHK syndrome had curvature of the spine, both scoliosis and kyphosis. People also had hip dysplasia; higher than average muscle tone and/or lower than average muscle tone; and defects of the extremities, including clubbed feet. Dental defects, including missing teeth, were common.

Vision and hearing issues

Some people with MKHK syndrome had strabismus (crossed eyes), other vision impairments, and hearing impairments.

  • 24 out of 40 people had strabismus (60 percent)
  • 12 out of 43 people had other vision impairments (28 percent)
  • 15 out of 40 people had hearing impairments (38 percent)
60%
24 out of 40 people had strabismus.
28%
12 out of 43 people had other vision impairments.
38%
15 out of 40 people had hearing impairments.

Where can I find support and resources?

Simons Searchlight

Simons Searchlight is an online international research program, building an ever growing natural history database, biorepository, and resource network of over 175 rare genetic neurodevelopmental disorders. By joining their community and sharing your experiences, you contribute to a growing database used by scientists worldwide to advance the understanding of your genetic condition. Through online surveys and optional blood sample collection, they gather valuable information to improve lives and drive scientific progress. Families like yours are the key to making meaningful progress. To register for Simons Searchlight, go to the Simons Searchlight website at www.simonssearchlight.org and click “Join Us.”

Sources and Reference

The content in this guide comes from published studies about EP300-related syndrome. Below you can find details about each study, as well as links to summaries or, in some cases, the full article.

  • Milani D. et al. Italian Journal of Pediatrics, 41, 4, (2015). Rubinstein-Taybi syndrome: Clinical features, genetic basis, diagnosis, and management www.ijponline.biomedcentral.com/articles/10.1186/s13052-015-0110-1
  • López M. et al. BMC Medical Genetics, 19, 36, (2018). Rubinstein-Taybi 2 associated to novel EP300 mutations: Deepening the clinical and genetic spectrum www.ncbi.nlm.nih.gov/pubmed/29506490
  • Haghshenas, S., Bout, H. J., Schijns, J. M., Levy, M. A., Kerkhof, J., Bhai, P., McConkey, H., Jenkins, Z. A., Williams, E. M., … Menke, L. A. (2024). Menke-Hennekam syndrome; delineation of domain-specific subtypes with distinct clinical and DNA methylation profiles. Human Genetic and Genomics Advances, 5(3), 100287. https://pubmed.ncbi.nlm.nih.gov/38553851/
  • Lacombe, D., Bloch-Zupan, A., Bredrup, C., Cooper, E. B., Houge, S. D., García-Miñaúr, S., Kayserili, H., Larizza, L., Lopez Gonzalez, V., … Hennekam, R. C. (2024). Diagnosis and management in Rubinstein-Taybi syndrome: First international consensus statement. Journal of Medical Genetics, 61(6), 503-519. https://pubmed.ncbi.nlm.nih.gov/38471765/
  • Stevens, C. A. Rubinstein-Taybi syndrome. 2003 Nov 9. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1526/

Follow Our Progress

Sign up for the Simons Searchlight newsletter.